Literature DB >> 25270038

The use of fondaparinux in pregnancy.

Esra Elsaigh1, Jecko Thachil, Michael J Nash, Clare Tower, Charles R M Hay, Sian Bullough, Louise Byrd.   

Abstract

Keywords:  allergy; fondaparinux; heparin; pregnancy

Mesh：

Substances：

Year:  2014        PMID： 25270038     DOI： 10.1111/bjh.13147

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.

Authors:  M Hoeltzenbein; E Beck; K Meixner; C Schaefer; R Kreutz
Journal:  Clin Res Cardiol       Date:  2015-07-21       Impact factor: 5.460

Review 2.  Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management.

Authors:  Paola Devis; M Grace Knuttinen
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

3.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.

Authors:  Shannon M Bates; Saskia Middeldorp; Marc Rodger; Andra H James; Ian Greer
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

4.  Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism.

Authors:  Samuel Adediran; Nicole Agostino
Journal:  Case Rep Hematol       Date:  2017-04-26

5.  Apixaban therapy in a pregnant woman with heparin-induced thrombocytopenia and venous thromboembolic events caused by congenital antithrombin deficiency: A case report.

Authors:  Mayuko Komori; Eijiro Hayata; Masahiko Nakata; Hitomi Yuzawa; Ayako Oji; Mineto Morita
Journal:  Case Rep Womens Health       Date:  2020-04-03

Review 6.  Supportive medication in cancer during pregnancy.

Authors:  Flora Zagouri; Nikolaos Dedes; Alkistis Papatheodoridi; Michael Liontos; Meletios Athanasios Dimopoulos
Journal:  BMC Pregnancy Childbirth       Date:  2020-12-01       Impact factor: 3.007

7.  Fondaparinux Pre-, Peri-, and/or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP).

Authors:  Carl-Erik Dempfle; Jürgen Koscielny; Edelgard Lindhoff-Last; Birgit Linnemann; Irene Bux-Gewehr; Günther Kappert; Ute Scholz; Stefan Kropff; Sonja Eberle; Peter Bramlage; Andreas Heinken
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.